Author: Aspen Neuroscience , Inc.

Posted Date:

March 18, 2026

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases

Aspen Neuroscience , Inc.

March 18, 2026
Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease

Aspen Neuroscience , Inc.

March 12, 2026